Inventiva SA
PAR:IVA
Inventiva SA
Common Stock
Inventiva SA
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Common Stock
€957k
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Common Stock
€24.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Innate Pharma SA
PAR:IPH
|
Common Stock
€4.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Common Stock
€12.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
DBV Technologies SA
PAR:DBV
|
Common Stock
$11m
|
CAGR 3-Years
19%
|
CAGR 5-Years
21%
|
CAGR 10-Years
22%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Common Stock
€3.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Common Stock?
Common Stock
957k
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Common Stock amounts to 957k EUR.
What is Inventiva SA's Common Stock growth rate?
Common Stock CAGR 3Y
34%
Over the last year, the Common Stock growth was 84%. The average annual Common Stock growth rates for Inventiva SA have been 34% over the past three years .
You don't have any saved screeners yet